Smith & Nephew soars 15% on clean result beat, reiterated 2025 guide

Published 05/08/2025, 07:40
Updated 05/08/2025, 11:02
© Reuters.

Investing.com -- Smith & Nephew (LON:SN) saw its shares soar 15% on Tuesday after it reported an 11.2% rise in first-half trading profit on Tuesday, supported by cost reductions and a rebound in its U.S. operations, which helped offset weaker demand from China.

The medical products maker posted trading profit of $523 million for the six months ended June 28, ahead of the $496 million expected by analysts. The trading profit margin improved to 17.7%, up from 16.7% a year earlier.

Revenue for the period rose to $2.96 billion, compared with $2.82 billion in the same period last year.

Operating profit increased 30.6% year-on-year to $429 million, while earnings per share reached 33.5 cents.

In the second quarter, organic sales growth (OSG) accelerated to 6.7%, ahead of the 4.5% consensus. Reported growth was 7.8%, including a 110 basis point benefit from foreign exchange.

Jefferies analysts said the company’s Q2 results "blew up expectations," 

Smith & Nephew reaffirmed its full-year 2025 guidance.

"Despite tougher comps in H2, the company seems on track to deliver the further step up expected in 2H25 to reach the reiterated FY25 guide of ~5% OSG," analysts wrote. 

The company announced a new $500 million share buyback to be executed in the second half of the year.

"This additional return of value will be undertaken in the second half of 2025 and reflects strong cash generation and balance sheet resulting from the 12-Point Plan transformation," Smith & Nephew said in the announcement. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.